HER2

Assets acting on this target.

Class
HER2-directed therapy
Pathway
HER2 signaling blockade / HER2-directed targeting in HER2-expressing tumors

HER2 (human epidermal growth factor receptor 2) is a receptor tyrosine kinase belonging to the ErbB/HER family of cell-surface growth factor receptors. In normal tissue it helps regulate cell growth and division, but in a subset of cancers (most notably certain breast and gastric tumors) the HER2 gene is amplified, causing the receptor to be overexpressed. This excess HER2 dimerizes readily with itself or other HER family members, continuously activating downstream growth pathways (including RAS-MAPK and PI3K-AKT) independent of normal growth signals, driving uncontrolled proliferation and survival of tumor cells. Because HER2 overexpression is confined largely to tumor cells relative to normal tissue, it serves as a rational target for selective anticancer therapy. Several distinct strategies exploit this: monoclonal and bispecific antibodies bind the extracellular domain to block receptor dimerization and flag cells for immune destruction; small-molecule tyrosine kinase inhibitors block the intracellular kinase directly, which can also reach the brain, relevant for metastatic disease; antibody-drug conjugates use HER2 binding to deliver cytotoxic payloads directly into tumor cells; and radiopharmaceuticals use HER2 binding to localize radiation. This mechanism broadly matters across HER2-driven breast, gastric, and other epithelial cancers.

By indication

Related mechanisms

HER2 drugs compared

17 drugs, stage by indication
17 drugs acting on HER2: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
margetuximabMargenzaTerSera Therapeutics LLCmonoclonal antibodyApprovedApproved in Breast Cancer; Approved in HER2-Positive Breast Cancer
Trastuzumab DeruxtecanAstraZeneca, Daiichi Sankyoantibody-drug conjugateApprovedApproved in Breast Cancer; Approved in HER2-Positive Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer; Approved in Non-Small Cell Lung Cancer
TucatinibMerck & Co., Pfizersmall moleculeApprovedApproved in Advanced Metastatic Colorectal Cancer; Approved in Breast Cancer; Approved in Colorectal Cancer; Approved in HER2-Positive Breast Cancer; Approved in Metastatic Colorectal Cancer; Phase 2 in Non-Small Cell Lung Cancer
ZanidatamabBeOne Medicines, Jazz Pharmaceuticals, Zymeworksbispecific antibodyApprovedApproved in Biliary Tract Cancer; Approved in Gastric Cancer; Phase 3 in HER2-Positive Breast Cancer; Phase 2 in Non-Small Cell Lung Cancer
Disitamab VedotinPfizer, RemeGen Co., Ltd.antibody-drug conjugatePhase 3Phase 3 in Gastric Cancer; Phase 3 in HR+/HER2- Metastatic Breast Cancer; Phase 3 in Urothelial Carcinoma; Phase 2/3 in HER2-Positive Breast Cancer; Phase 2 in Non-Small Cell Lung Cancer
Trastuzumab brengitecanSichuan Baili Pharmaceuticalantibody-drug conjugatePhase 3Phase 3 in Biliary Tract Cancer; Phase 3 in Colorectal Cancer; Phase 3 in HER2-Positive Breast Cancer; Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Ovarian Cancer; Phase 3 in Urothelial Carcinoma
Trastuzumab pamirtecanBioNTech, DualityBio Inc.antibody-drug conjugatePhase 3Phase 3 in Endometrial Cancer; Phase 3 in HER2-Positive Breast Cancer; Phase 3 in HR+/HER2- Metastatic Breast Cancer
Trastuzumab rezetecanGlenmark Pharmaceuticals Ltd., Jiangsu Hengrui Pharmaceuticalsantibody-drug conjugatePhase 3Phase 3 in Breast Cancer; Phase 3 in Colorectal Cancer; Phase 3 in Gastric Cancer; Phase 3 in HER2-Positive Breast Cancer; Phase 3 in HR+/HER2- Metastatic Breast Cancer; Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Ovarian Cancer
BizrolertinibRochesmall moleculePhase 2/3Phase 2/3 in HER2-Positive Breast Cancer
HRS-4508Jiangsu Hengrui Pharmaceuticalssmall moleculePhase 2Phase 2 in Non-Small Cell Lung Cancer
177Lu-DWJ155NovartisradiopharmaceuticalPhase 1Phase 1 in Non-Small Cell Lung Cancer
BL-M17D1SystImmuneantibody-drug conjugatePhase 1Phase 1 in Non-Small Cell Lung Cancer
KJ015Shanghai Bao Pharmaceuticals Co., Ltd.bispecific antibody (biparatopic)Phase 1Phase 1 in Non-Small Cell Lung Cancer
MT-304CREATE MedicinesmRNA (in vivo CAR, LNP)Phase 1Not recorded
NVL-330GlaxoSmithKline, Nuvalent, Inc.small moleculePhase 1Phase 1 in HER2-Mutant Non-Small Cell Lung Cancer; Phase 1 in Non-Small Cell Lung Cancer
RAD202Radiopharm Theranostics, LtdradiopharmaceuticalPhase 1Phase 1 in HER2-Positive Advanced Solid Tumors
GSK6855547GlaxoSmithKlinesmall moleculeStage not recordedNot recorded

← all mechanisms